|
Vaccine Detail
L. amazonensis CP Protein Vaccine |
Vaccine Information |
- Vaccine Name: L. amazonensis CP Protein Vaccine
- Target Pathogen: Leishmania amazonensis
- Target Disease: Leishmaniasis
- Vaccine Ontology ID: VO_0004199
- Type: Subunit vaccine
- Status: Research
- Host Species as Laboratory Animal Model: mouse
- Antigen: A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24 (Fedeli et al., 2010).
- CP cysteine proteinase
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Immunization Route: subcutaneous injection
|
Host Response |
Mouse Response
- Host Strain: BALB/c
- Vaccination Protocol: Female BALB/c mice (six per group) were immunized thrice with a 2 week interval with 25 μg of rLacys24 plus complete Freund’s adjuvant (CFA) by the subcutaneous route in the base of the tail. Control animals received PBS or only adjuvant (Fedeli et al., 2010).
- Challenge Protocol: Two weeks after the last dose animals were challenged with 2.5 × 10^5 L. (L.) amazonensis amastigotes in PBS in the hind footpad (Fedeli et al., 2010).
- Efficacy: Immunization of BALB/c mice with rLacys24 plus CFA adjuvant resulted in a low but significant decrease of foot lesions after challenge with L. (L.) amazonensis compared to those exhibited by control mice (Fedeli et al., 2010).
|
References |
Fedeli et al., 2010: Fedeli CE, Ferreira JH, Mussalem JS, Longo-Maugéri IM, Gentil LG, dos Santos MR, Katz S, Barbiéri CL. Partial protective responses induced by a recombinant cysteine proteinase from Leishmania (Leishmania) amazonensis in a murine model of cutaneous leishmaniasis. Experimental parasitology. 2010; 124(2); 153-158. [PubMed: 19735658].
|
|